Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Wenxin LuoZhoufeng WangPanwen TianWei-Min LiPublished in: Journal of cancer research and clinical oncology (2018)
PD-1/PD-L1 inhibitors are generally safer and better tolerated than chemotherapy for patients with NSCLC with regard to summary toxic events, detailed toxic symptoms and hematologic toxicities. However, PD-1/PD-L1 inhibitors can generate a unique spectrum of irAEs, and several of them can be severe and even life-threatening. Clinicians should be aware of the risk of these AEs, as they may have a potentially negative impact on the patients' quality of life and survival outcome.
Keyphrases
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- systematic review
- peritoneal dialysis
- prognostic factors
- clinical trial
- early onset
- randomized controlled trial
- open label
- advanced non small cell lung cancer
- locally advanced
- depressive symptoms
- brain metastases
- drug induced
- placebo controlled
- chemotherapy induced